Reconsidering the rVSVΔG-ZEBOV-GP vaccine during the 2026 Bundibugyo virus outbreak

The Lancet Infectious Diseases·July 20

Infectious Diseases Bundibugyo Virus Disease Ebola Virus Disease Live Recombinant Vesicular Stomatitis Virus Vaccine Ervebo RVSVΔG-ZEBOV-GP

Summary

View source

What was studied

The paper reconsiders the use of the rVSVΔG-ZEBOV-GP vaccine (licensed for Ebola virus disease caused by Zaire ebolavirus) during a 2026 outbreak of Bundibugyo virus (BDBV), a distinct Ebolavirus species.

Reconsidering the rVSVΔG-ZEBOV-GP vaccine during the 2026 Bundibugyo virus outbreak

Summary

What was studied

Related Questions

Reconsidering the rVSVΔG-ZEBOV-GP vaccine during the 2026 Bundibugyo virus outbreak

Summary

What was studied

Related Questions